PTEN and glioblastoma: To determine if combination kinase targeting affected GBM survival, PTEN-deficient Mayo59 gliomaspheres were selected for intracranial tumor modeling, considering the magnitude of the reduction in gliomasphere mean area (Fig. 2C and D).